Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.APP Pharmaceuticals, a fully integrated pharmaceutical company, has announced that Fresenius Kabi, a business segment of Fresenius SE, has completed its acquisition of APP.
Subscribe to our email newsletter
Fresenius Kabi has said that the acquisition is an important step in its growth strategy. Through APP, Fresenius Kabi enters the US pharmaceuticals market and is likely to consolidate its position in the global I.V. generics industry.
Patrick Soon-Shiong, founder of APP and former chairman of the board, said: “By joining forces with Fresenius Kabi we have a unique opportunity to bring together two successful businesses, with complementary philosophies, cultures and business models.
“The combined expertise and expanded infrastructure will help to ensure that we can realize our commitment to patient care on a global basis. We look forward to working closely with Fresenius as we aim to achieve our respective growth strategies.”
Dr Soon-Shiong also said that APP will operate as the North American platform for Fresenius Kabi and its products will continue to be sold under the ‘APP Pharmaceuticals’ brand name. Additionally, he will become a member of the Fresenius Kabi board of directors.